The “newer” progestogens and postmenopausal hormone therapy (HRT)

Adolf E. Schindler
In: The Journal of Steroid Biochemistry and Molecular Biology · 2013 · vol. 142 , pp. 48–51 · doi:10.1016/j.jsbmb.2013.12.003 · PMID:24333799 · W2099502315
review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

This review discusses newer progestogens used in postmenopausal hormone therapy, focusing on their formulations, mechanisms, and clinical outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

After a worldwide breakdown of hormone therapy [HT] following the publications of the Women's Health Initiative trial and Million Women's Study in 2002-2003, there is now a trend to turn attention again to HT and to explore particular progestogens, which have been discredited with respect to their side effects. The progestogens to be considered should control undue proliferation of the endometrium and should not interfere negatively with the positive effects of estradiol, regarding carbohydrate and lipid metabolism as well as hemostasis. In the present review, three "newer progestogens" are scrutinized regarding their various actions, in combination with estradiol; the progestogens include dienogest, drospirenone and nomegestrol acetate. This article is part of a special issue entitled Menopause.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (25)

Source provenance

openalex
last seen: 2026-05-11T05:56:47.744056+00:00
License: CC0 · commercial use OK